+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010623
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Immunotherapy Drug Discovery Outsourcing Market grew from USD 1.84 billion in 2024 to USD 2.14 billion in 2025. It is expected to continue growing at a CAGR of 15.68%, reaching USD 4.42 billion by 2030.

Laying the Groundwork for Transformative Cancer Immunotherapy Drug Discovery Outsourcing Models to Accelerate Development and Foster Collaborative Breakthroughs

The landscape of cancer immunotherapy drug discovery is undergoing a profound transformation, driven by advancements in molecular biology, bioengineering, and data analytics. As the scientific frontier expands, organizations are seeking specialized expertise and scalable capabilities to accelerate their pipelines. In response, outsourcing partners are emerging as critical enablers-providing access to advanced technologies, regulatory know-how, and operational efficiencies that internal teams may find difficult to replicate.

By forging strategic collaborations with contract research organizations and specialized service providers, companies can de-risk development timelines and allocate resources more effectively. Such partnerships extend beyond mere execution of laboratory tasks; they foster knowledge exchange, drive innovation, and catalyze clinical success. Consequently, outsourcing is no longer a cost-containment strategy alone but a catalyst for scientific breakthroughs.

This executive summary presents an in-depth exploration of the current state and emerging trends in cancer immunotherapy drug discovery outsourcing. It highlights transformative shifts in the market dynamics, assesses the impact of newly imposed tariffs, elucidates segmentation and regional insights, and profiles leading organizations shaping the field. Additionally, it outlines actionable recommendations to help decision-makers optimize their outsourcing strategies and achieve sustainable competitive advantage.

Mapping the Shifting Paradigm in Cancer Immunotherapy Through Outsourcing as Technological Advances and Stakeholder Expectations Realign Industry Dynamics

The oncology research ecosystem has experienced several converging forces that are reshaping how immunotherapy drug discovery is conducted and outsourced. Technological breakthroughs in single-cell sequencing, artificial intelligence-driven target identification, and advanced process development have expanded the scope and complexity of projects, necessitating partners with highly specialized capabilities. Simultaneously, the shift towards personalized medicine has raised the bar for precision and flexibility, compelling sponsors to seek agile collaborators capable of tailoring solutions to unique molecular profiles.

In parallel, regulatory authorities worldwide are refining guidelines for immunotherapy products, introducing new requirements for safety assessments, manufacturing controls, and post-approval surveillance. This evolving regulatory landscape underscores the value of service providers with deep compliance expertise who can seamlessly navigate filings and inspections. Moreover, the increasing emphasis on cost-effectiveness and speed to clinic, driven by investor and healthcare payer pressures, has accelerated the adoption of integrated outsourcing models that combine discovery, development, and manufacturing support under a unified framework.

Taken together, these transformative shifts are steering cancer immunotherapy drug discovery toward a more collaborative, technology-enabled, and risk-balanced paradigm. Organizations that proactively align with the right outsourcing partners can harness these changes to drive innovation, reduce time to market, and deliver life-saving therapies to patients faster than ever before.

Examining the Cascading Effects of Newly Imposed United States Tariffs in 2025 on Global Cancer Immunotherapy Outsourcing and Supply Chain Optimization

In 2025, the introduction of new United States tariffs on key raw materials and specialized reagents is expected to reverberate across global supply chains in cancer immunotherapy drug discovery. These measures will likely increase the cost of sourcing critical components such as cytokine reagents, viral vectors, and custom peptides from domestic and international suppliers. As a result, organizations must evaluate the total landed cost of materials and reassess their supply chain strategies to mitigate pricing pressures and delivery delays.

Beyond immediate cost implications, the tariffs may prompt sponsors to diversify their supplier base and explore alternative manufacturing locations in lower-cost regions. By strategically reallocating certain preclinical or manufacturing activities to partners in Europe, Asia-Pacific, or the Middle East, companies can optimize their global footprints and maintain continuity in development programs. Furthermore, tariff-driven cost increases may spur demand for process intensification and continuous manufacturing approaches, as sponsors seek to enhance yields and reduce material consumption.

Ultimately, the 2025 tariff landscape represents both a challenge and an opportunity. While sponsors face elevated procurement costs and potential supply disruptions, those that proactively adapt their outsourcing frameworks-by adopting flexible sourcing strategies, negotiating long-term agreements, and leveraging advanced process technologies-will strengthen their resilience and competitive positioning in the immunotherapy arena.

Unearthing Deep Segmentation Insights to Navigate Service Types Therapeutic Modalities Workflow Stages and End User Dynamics in Immunotherapy Outsourcing

A deep dive into service type segmentation reveals a layered ecosystem of research and development activities. Clinical development services encompass Phase I safety assessments, Phase II efficacy evaluations, and Phase III pivotal trials, each demanding distinct regulatory, statistical, and operational expertise. Data management and biostatistics partners integrate bioinformatics analyses with clinical data management platforms and robust statistical modeling to ensure that trial outcomes are reliable and regulatory-ready. On the manufacturing side, CMC optimization and process development specialists work hand in hand to scale up production processes while maintaining critical quality attributes of complex immunotherapy molecules. Preclinical services cover the full spectrum from hit and lead discovery through toxicology assessments and target identification, establishing the scientific foundation for clinical progression. Regulatory affairs support providers guide sponsors through IND filings, liaise with health authorities, and develop comprehensive regulatory strategies tailored to each geolocation.

Therapeutic modality segmentation highlights the diversity of immunotherapeutic approaches. Cancer vaccines-including dendritic cell-based formulations, DNA, peptide, and RNA platforms-require partners proficient in antigen selection, delivery systems, and immunogenicity assessment. CAR T cell therapies, whether BCMA or CD19 targeted, hinge on specialized cell processing capabilities, retroviral vector production, and stringent safety testing. Checkpoint inhibitors, spanning CTLA-4, PD-1, and PD-L1 targets, demand robust antibody engineering, preclinical validation, and manufacturing process controls. Cytokine therapies focused on colony stimulating factors, interferons, and interleukins rely on optimized expression systems and high-throughput screening. Monoclonal antibodies vary from murine and chimeric to humanized and fully human constructs, each necessitating tailored cell line development and purification strategies. Oncolytic virus therapies leverage adenovirus, HSV, or reovirus backbones, calling for high-containment manufacturing suites and specialized safety testing protocols.

Workflow stage segmentation underscores the end-to-end nature of outsourcing needs. Discovery stage partners facilitate hit validation, lead discovery, and target identification through state-of-the-art screening platforms and in silico modeling. IND enabling and preclinical development entities manage toxicology studies and formulation optimization to prepare for regulatory submissions. Clinical stage outsourcing firms handle Phase I through Phase III execution, patient enrollment, and site management, while post-approval stage providers conduct pharmacovigilance and Phase IV studies. Finally, end user segmentation captures the varied customer base: academic research institutes pioneering early-stage science, biotech companies accelerating niche innovation, government research bodies funding foundational programs, and large pharmaceutical firms orchestrating global development initiatives.

Evaluating Regional Dynamics and Growth Opportunities Across the Americas Europe Middle East Africa and Asia Pacific in Cancer Immunotherapy Outsourcing

The Americas region remains a powerhouse for cancer immunotherapy outsourcing, driven by a mature biotech ecosystem, leading research universities, and robust venture capital support. Advanced cell therapy manufacturing facilities and specialized clinical trial networks have flourished across North America, while Latin American countries are gradually emerging as attractive destinations for cost-efficient preclinical studies and patient recruitment. Moreover, progressive regulatory frameworks in the United States and Canada facilitate expedited pathways, reinforcing the region’s leadership position.

Europe, Middle East & Africa presents a tapestry of opportunity and complexity. Western Europe houses established contract research organizations with deep oncology expertise and integrated manufacturing services. Countries in the Middle East are investing heavily in biotech clusters and regulatory harmonization, aiming to become regional hubs for clinical research. At the same time, parts of Africa are beginning to host early-phase clinical trials for localized indications, supported by growing public-private partnerships and infrastructure development initiatives.

Asia-Pacific continues its trajectory as a dynamic growth frontier, with major markets such as China, Japan, South Korea, and Singapore expanding their capabilities in immunotherapy R&D. Localized manufacturing support, favorable government incentives, and large patient populations drive increasing clinical trial activity. In parallel, emerging markets in Southeast Asia and Australia offer specialized preclinical services and collaborative research models. Collectively, the Asia-Pacific region provides a compelling mix of scale, cost competitiveness, and scientific talent that sponsors can leverage to diversify their outsourcing portfolios.

Profiling Leading Contract Research Organizations and Biotech Innovators Accelerating Key Advances in Cancer Immunotherapy Drug Discovery Outsourcing

Leading contract research organizations and biotech innovators are at the forefront of reshaping cancer immunotherapy outsourcing. Some global CROs have expanded their cell therapy capacities, fortified biologics manufacturing suites, and integrated AI-driven analytics platforms to deliver seamless discovery-to-clinical solutions. Concurrently, specialized biotech enterprises have carved niches in antigen discovery, novel vector design, and adaptive immunomonitoring, attracting strategic collaborations with both emerging and established sponsors.

These organizations are differentiating themselves through targeted investments in automation, quality management systems, and digital data ecosystems. By adopting continuous manufacturing techniques and modular facility architectures, they are reducing lead times and increasing production flexibility. Moreover, several emerging players are forging alliances with academic medical centers and patient advocacy groups to co-develop biomarkers and real-world evidence programs that inform clinical trial design and regulatory engagement.

In the competitive landscape, success hinges on demonstrable scientific expertise, geographic reach, and the ability to deliver patient-centric solutions. Companies that combine niche therapeutic modality knowledge with global operational footprint are securing long-term partnerships, while nimble startups focused on cutting-edge technologies are driving disruptive innovations. Together, these leading organizations are establishing new benchmarks in efficiency, quality, and translational insight across the immunotherapy outsourcing value chain.

Implementing Actionable Recommendations to Enhance Strategic Outsourcing Frameworks and Propel Next Generation Cancer Immunotherapy Development Initiatives

To capitalize on the evolving immunotherapy outsourcing landscape, industry leaders should pursue a multi-pronged approach that balances innovation with operational rigor. First, forging strategic alliances with service providers that demonstrate specialized expertise in emerging modalities will enable sponsors to access differentiated capabilities without diluting internal resources. Second, implementing a flexible supplier management framework-incorporating regional diversification, dual sourcing, and scenario planning-will mitigate the impact of geopolitical shifts and tariff disruptions on program timelines and budgets.

Furthermore, investing in digital platforms that unify project management, data analytics, and quality oversight will enhance real-time decision-making and reduce administrative overhead. Organizations should also engage in early dialogue with regulatory authorities and leverage adaptive trial designs to streamline development pathways and accelerate clinical milestones. Finally, fostering collaborative innovation ecosystems-through academic partnerships, consortium participation, and open innovation challenges-will facilitate access to novel targets, biomarkers, and precompetitive data sets that can de-risk candidate selection.

By integrating these actionable recommendations, industry leaders can navigate complexity, optimize resource allocation, and unlock new efficiencies. Ultimately, a proactive, data-driven outsourcing strategy will position organizations to deliver next-generation immunotherapies with greater speed, quality, and patient impact.

Outlining a Comprehensive Research Methodology Combining Qualitative and Quantitative Techniques for Rigorous Analysis of Cancer Immunotherapy Outsourcing

This research leverages a hybrid methodology combining both qualitative and quantitative techniques to ensure comprehensive and rigorous analysis. Primary research comprised one-on-one interviews with senior executives, scientific directors, and clinical leads from leading pharmaceutical firms, biotechnology companies, and contract research organizations. These in-depth discussions provided firsthand insights into outsourcing strategies, technology adoption, and regional dynamics.

Secondary research entailed a thorough review of peer-reviewed journals, regulatory guidelines, company white papers, and patent filings to validate trends and identify emerging scientific breakthroughs. Quantitative data streams included industry databases, clinical trial registries, and trade publications, which were triangulated to establish patterns in service utilization, therapeutic modality preferences, and geographic distribution of outsourcing activities.

Data integrity was upheld through cross-validation across multiple sources, while key findings were subjected to expert panel review to eliminate bias and ensure actionable clarity. This multifaceted approach delivers a robust evidence base, equipping stakeholders with the insights needed to make informed strategic decisions in the dynamic cancer immunotherapy outsourcing arena.

Drawing Together Key Findings and Strategic Takeaways to Summarize Insights on Cancer Immunotherapy Outsourcing and Future Industry Trajectories

In summary, the cancer immunotherapy drug discovery outsourcing landscape is experiencing dynamic shifts driven by technological innovation, regulatory evolution, and global supply chain realignment. Strategic segmentation across service types, therapeutic modalities, workflow stages, and end users underscores the need for tailored partnership models that address specialized scientific and operational requirements. Regional insights highlight the Americas as a mature hub, Europe, Middle East & Africa as a diverse emergent market, and Asia-Pacific as a rapidly expanding frontier offering scale and cost efficiencies.

Key industry players are differentiating through advanced manufacturing capabilities, digital integration, and collaborative innovation frameworks. Meanwhile, the projected impact of United States tariffs in 2025 necessitates proactive supply chain diversification and cost management strategies. By embracing the actionable recommendations outlined-such as flexible sourcing, digital transformation, and early regulatory engagement-organizations can strengthen resilience and expedite pipeline progression.

As the field advances, those who adopt a holistic, data-driven outsourcing approach will be best positioned to deliver transformative immunotherapies to patients worldwide. The insights and strategies articulated herein serve as a blueprint for stakeholders seeking to navigate this complex and high-impact domain with confidence and precision.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Clinical Development Services
      • Phase I
      • Phase II
      • Phase III
    • Data Management And Biostatistics
      • Bioinformatics
      • Clinical Data Management
      • Statistical Analysis
    • Manufacturing Support
      • CMC Optimization
      • Process Development
    • Preclinical Services
      • Hit And Lead Discovery
      • Lead Optimization
      • Preclinical Safety Assessment
      • Target Identification
    • Regulatory Affairs Support
      • IND Filing Support
      • Regulatory Strategy Consulting
  • Therapeutic Modality
    • Cancer Vaccines
      • Dendritic Cell Vaccines
      • DNA Vaccines
      • Peptide Vaccines
      • RNA Vaccines
    • CAR T Cell Therapy
      • BCMA Targeted
      • CD19 Targeted
    • Checkpoint Inhibitors
      • CTLA-4 Inhibitors
      • PD-1 Inhibitors
      • PD-L1 Inhibitors
    • Cytokine Therapy
      • Colony Stimulating Factors
      • Interferons
      • Interleukins
    • Monoclonal Antibodies
      • Chimeric
      • Fully Human
      • Humanized
      • Murine
    • Oncolytic Virus Therapy
      • Adenovirus Based
      • HSV Based
      • Reovirus Based
  • Workflow Stage
    • Clinical Stage
      • Phase I
      • Phase II
      • Phase III
    • Development Stage
      • IND Enabling Studies
      • Preclinical Development
    • Discovery Stage
      • Hit Discovery
      • Hit Validation
      • Lead Discovery
      • Target Identification
    • Post Approval Stage
      • Pharmacovigilance
      • Phase IV Studies
  • End User
    • Academic Research Institutes
    • Biotechnology Companies
    • Government Research Institutes
    • Pharmaceutical Companies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Syneos Health, Inc.
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • ICON plc
  • WuXi AppTec Co., Ltd.
  • GenScript Biotech Corporation
  • Evotec SE

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of AI-driven target discovery platforms accelerating identification of novel tumor antigens
5.2. Increasing collaborations between biotech startups and CROs for development of personalized neoantigen vaccines
5.3. Expansion of cell therapy outsourcing services for CAR-T manufacturing and optimization across global CDMOs
5.4. Growing integration of single-cell sequencing technologies to profile tumor microenvironment in immunotherapy trials
5.5. Rising demand for biomarker-driven patient stratification solutions to improve immunotherapy clinical outcomes
5.6. Implementation of digital twin models to simulate immunotherapeutic drug responses for preclinical screening
5.7. Emergence of allogeneic NK cell therapy outsourcing to streamline off-the-shelf cancer immunotherapy production
5.8. Strategic partnerships focused on bispecific antibody discovery platforms targeting dual immune checkpoints
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type
8.1. Introduction
8.2. Clinical Development Services
8.2.1. Phase I
8.2.2. Phase II
8.2.3. Phase III
8.3. Data Management And Biostatistics
8.3.1. Bioinformatics
8.3.2. Clinical Data Management
8.3.3. Statistical Analysis
8.4. Manufacturing Support
8.4.1. CMC Optimization
8.4.2. Process Development
8.5. Preclinical Services
8.5.1. Hit And Lead Discovery
8.5.2. Lead Optimization
8.5.3. Preclinical Safety Assessment
8.5.4. Target Identification
8.6. Regulatory Affairs Support
8.6.1. IND Filing Support
8.6.2. Regulatory Strategy Consulting
9. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Modality
9.1. Introduction
9.2. Cancer Vaccines
9.2.1. Dendritic Cell Vaccines
9.2.2. DNA Vaccines
9.2.3. Peptide Vaccines
9.2.4. RNA Vaccines
9.3. CAR T Cell Therapy
9.3.1. BCMA Targeted
9.3.2. CD19 Targeted
9.4. Checkpoint Inhibitors
9.4.1. CTLA-4 Inhibitors
9.4.2. PD-1 Inhibitors
9.4.3. PD-L1 Inhibitors
9.5. Cytokine Therapy
9.5.1. Colony Stimulating Factors
9.5.2. Interferons
9.5.3. Interleukins
9.6. Monoclonal Antibodies
9.6.1. Chimeric
9.6.2. Fully Human
9.6.3. Humanized
9.6.4. Murine
9.7. Oncolytic Virus Therapy
9.7.1. Adenovirus Based
9.7.2. HSV Based
9.7.3. Reovirus Based
10. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Workflow Stage
10.1. Introduction
10.2. Clinical Stage
10.2.1. Phase I
10.2.2. Phase II
10.2.3. Phase III
10.3. Development Stage
10.3.1. IND Enabling Studies
10.3.2. Preclinical Development
10.4. Discovery Stage
10.4.1. Hit Discovery
10.4.2. Hit Validation
10.4.3. Lead Discovery
10.4.4. Target Identification
10.5. Post Approval Stage
10.5.1. Pharmacovigilance
10.5.2. Phase IV Studies
11. Cancer Immunotherapy Drug Discovery Outsourcing Market, by End User
11.1. Introduction
11.2. Academic Research Institutes
11.3. Biotechnology Companies
11.4. Government Research Institutes
11.5. Pharmaceutical Companies
12. Americas Cancer Immunotherapy Drug Discovery Outsourcing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. IQVIA Holdings Inc.
15.3.2. Laboratory Corporation of America Holdings
15.3.3. Thermo Fisher Scientific Inc.
15.3.4. Syneos Health, Inc.
15.3.5. Parexel International Corporation
15.3.6. Charles River Laboratories International, Inc.
15.3.7. ICON plc
15.3.8. WuXi AppTec Co., Ltd.
15.3.9. GenScript Biotech Corporation
15.3.10. Evotec SE
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: RESEARCHAI
FIGURE 24. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: RESEARCHSTATISTICS
FIGURE 25. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: RESEARCHCONTACTS
FIGURE 26. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Immunotherapy Drug Discovery Outsourcing market report include:
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Syneos Health, Inc.
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • ICON plc
  • WuXi AppTec Co., Ltd.
  • GenScript Biotech Corporation
  • Evotec SE

Table Information